natgillin/translations-raw huggingface dataset:
The 3 mg tablets are white and printed with “PAL 3”, the 6 mg tablets are beige and printed with “PAL 6”, the 9 mg tablets are pink and printed with “PAL 9”, and the 12 mg tablets are dark yellow and printed with “PAL 12”. 
3 mg tablete so bele z oznako “PAL 3”, 6 mg tablete so rjavkaste z oznako “PAL 6”, 9 mg tablete so roza z oznako “PAL 9” in 12 mg tablete so temno rumene z oznako “PAL 12”.
The patient should be instructed to always take INVEGA in the fasting state or always take it together with breakfast and not to alternate between administration in the fasting state or in the fed state. 
Bolniku naročite, naj zdravilo INVEGA jemlje bodisi vedno na tešče ali pa vedno z zajtrkom in naj ne spreminja načina jemanja, to je naj zdravila ne jemlje enkrat na tešče in enkrat z zajtrkom.
In the lower dose group of the 2 dose-level study (6 mg/day with option to reduce to 3 mg/day), INVEGA was not significantly different from placebo as measured by the PANSS. 
V študiji z dvema ravnema odmerkov, v skupini, v kateri so preiskovanci prejemali manjši odmerek (6 mg/dan z možnostjo zmanjšanja na 3 mg/dan), se zdravilo INVEGA ni bistveno razlikovalo od placeba pri rezultatu vprašalnika PANSS.
Each bottle contains two 1 g dessicant silica gel (silicone dioxide) pouches (pouch is food approved polyethylene). 
En vsebnik vsebuje dve vrečki (iz polietilena, odobrenega za uporabo pri pakiranju živil) z 1 g sušilnega sredstva iz silikagela (silicijevega dioksida).
Pack sizes of 14, 28, 49, 56, and 98 prolonged-release tablets. 
Velikosti pakiranj: 14, 28, 49, 56 in 98 tablet s podaljšanim sproščanjem.
QT prolongation, ventricular arrythmias (ventricular fibrillation, ventricular tachycardia), sudden unexplained death, cardiac arrest and Torsade de pointes may occur with antipsychotics. 
Pri uporabi antipsihotikov, lahko pride do podaljšanja QT intervala, ventrikularnih aritmij (ventrikularna fibrilacija, ventrikularna tahikardija), nenadne nepričakovane smrti, srčnega zastoja in Torsade de pointes.
White high-density polyethylene (HDPE) bottle with induction sealing and polypropylene child-resistant closure. 
Beli vsebniki iz polietilena velike gostote (HDPE) z indukcijsko zaporo in polipropilensko zaporko, varno za otroke.
Neuroleptic Malignant Syndrome (NMS), characterised by hyperthermia, muscle rigidity, autonomic instability, altered consciousness, and elevated serum creatine phosphokinase levels has been reported to occur with paliperidone. 
Poročali so, da se pri uporabi paliperidona lahko pojavi nevroleptični maligni sindrom (NMS), za katerega so značilni hipertermija, mišična rigidnost, avtonomna nestabilnost, spremenjeno stanje zavesti in zvišana serumska koncentracija kreatin fosfokinaze.
Posology 
VSEBNIK
• a blockage in the bowels, stool incontinence, very hard stool, lack of bowel muscle movement that causes blockage 
• zaprtje črevesja, nezmožnost zadrževanja blata, zelo trdo blato, zmanjšano gibanje črevesa, ki povzroči zastoj
Caution is advised if paliperidone is combined with other medicines known to lower the seizure threshold (i.e., phenothiazines or butyrophenones, clozapine, tricyclics or SSRIs, tramadol, mefloquine, etc.). 
Če se paliperidon uporablja sočasno z zdravili, ki znižajo prag za krče oz. epileptične napade (npr. fenotiazini ali butirofenoni, klozapin, triciklični antidepresivi ali SSRI, tramadol meflokin itd.) je potrebna previdnost.
Hypromellose Titanium dioxide (E171) Lactose monohydrate Triacetin 
Obloga hipromeloza titanov dioksid (E171) laktoza monohidrat triacetin karnauba vosek
With once-daily dosing of INVEGA, steady-state concentrations of paliperidone are attained within 4-5 days of dosing in most subjects. 
Pri odmerjanju zdravila INVEGA enkrat na dan je bila pri večini preiskovancev koncentracija paliperidona v stanju dinamičnega ravnovesja dosežena v 4 do 5 dneh jemanja zdravila.
Some patients may benefit from lower or higher doses within the recommended range of 3 mg to 12 mg once daily. 
Nekaterim bolnikom lahko pomagajo tudi manjši ali večji odmerki, v razponu priporočenih odmerkov od 3 mg do 12 mg enkrat na dan.
Undesirable effects noted with risperidone formulations Paliperidone is the active metabolite of risperidone, therefore, the adverse reaction profiles of these compounds (including both the oral and injectable formulations) are relevant to one another. 
Neželeni učinki poročani z različnimi oblikami risperidona Paliperidon je aktivni presnovek risperidona, zato sta njuna profila neželenih učinkov (peroralne oblike in injekcije) odvisna eden od drugega.
Concomitant use of INVEGA with oral risperidone is not recommended as paliperidone is the active metabolite of risperidone and the combination of the two may lead to additive paliperidone exposure. 
Sočasna uporaba zdravila INVEGA in risperidona Sočasne uporabe zdravila INVEGA s peroralnim risperidonom ni priporočljiva, ker je paliperidon aktivni presnovek risperidona, zato lahko pri sočasni uporabi obeh pride do aditivne izpostavljenosti paliperidonu.
EPS included a pooled analysis of the following terms: Parkinsonism (includes salivary hypersecretion, musculoskeletal stiffness, parkinsonism, drooling, cogwheel rigidity, bradykinesia, hypokinesia, masked facies, muscle tightness, akinesia, nuchal rigidity, muscle rigidity, parkinsonian gait, and glabellar reflex abnormal, parkinsonian rest tremor), akathisia (includes akathisia, restlessness, hyperkinesia, and restless leg syndrome), dyskinesia (dyskinesia, muscle twitching, choreoathetosis, athetosis, and myoclonus), dystonia (includes dystonia, hypertonia, torticollis, muscle contractions involuntary, muscle contracture, blepharospasm, oculogyration, tongue paralysis, facial spasm, laryngospasm, myotonia, opisthotonus, oropharyngeal spasm, pleurothotonus, tongue spasm, and trismus), and tremor. 
Pri EPS so opravili tudi analizo zbranih podatkov za naslednje izraze: parkinsonizem (vključuje hipersekrecijo sline, otrdelost mišic, parkinsonizem, slinjenje, rigidnost tipa zobatega kolesa, bradikinezijo, hipokinezijo, obraz kot maska, napetost mišic, akinezijo, rigidnost vratu, rigidnost mišic, parkinsonsko držo, nenormalni glaberalni refleks), parkinsonski tremor v mirovanju; akatizija (vključuje akatizijo, nemir, hiperkinezijo in sindrom nemirnih nog); diskinezija (diskinezija, trzanje mišic, horeoatetoza, atetoza in mioklonus); distonija (vključuje distonijo, hipertonijo, tortikolis, nenadzorovano krčenje mišic, krčenje mišic, blefarospazem, okulogiracijo, paralizo jezika, obrazne krče, laringospazem, miotonijo, opistotonus, orofaringealne krče, plevrototonus, krče jezika in trizmus) in tremor.
Because of its potential for inducing orthostatic hypotension (see section 4.4), an additive effect may be observed when INVEGA is administered with other therapeutic agents that have this potential, e.g., other antipsychotics, tricyclics. 
Ker to zdravilo lahko povzroči ortostatsko hipotenzijo (glejte poglavje 4.4), pri sočasni uporabi zdravila INVEGA in drugih zdravil z enakim delovanjem npr.: drugi antipsihotiki, triciklični antidepresivi lahko opazimo aditivni učinek.
Some patients may benefit from higher doses within the recommended range of 6 mg to 12 mg once daily. 
Nekaterim bolnikom lahko pomagajo tudi večji odmerki, v razponu priporočenih odmerkov od 6 mg do 12 mg enkrat na dan.
Response defined as decrease from baseline in PANSS Total Score ≥ 30% and CGI-C Score ≤ 2 
Odziv je opredeljen kot zmanjšanje celotnega rezultata PANSS za ≥ 30 % in rezultata CGI-C za ≤ 2 od izhodiščne vrednosti.
In schizoaffective disorder clinical trials, a higher percentage of INVEGA-treated subjects (5%) had an increase in body weight of ≥ 7% compared with placebo-treated subjects (1%). 
V kliničnih preskušanjih shizoafektivne motnje je bilo povečanje telesne mase za ≥ 7% večje pri preiskovancih, ki so prejemali zdravilo INVEGA (5%), kot pri preiskovancih, ki so prejemali placebo (1%).
3 mg tablets Contains lactose. 
3 mg tablete Vsebujejo laktozo.
The efficacy of INVEGA in the treatment of schizophrenia in adolescents between 12 and 14 years old has not been established. 
Učinkovitosti zdravila INVEGA pri zdravljenju shizofrenije pri mladostnikih, starih med 12 in 14 let, niso dokazali.
Response defined as decrease from baseline in PANSS Total Score ≥ 20% Note: Negative change in score indicates improvement. 
Odgovor je opredeljen kot zmanjšanje skupnega rezultata PANSS za ≥ 20% od izhodiščne vrednosti.
Patients with a history of a clinically significant low white blood cell count (WBC) or a drug-induced leucopenia/neutropenia should be monitored during the first few months of therapy and discontinuation of INVEGA should be considered at the first sign of a clinically significant decline in WBC in the absence of other causative factors. 
Bolnike, ki so že imeli klinično pomembno majhno število levkocitov (WBC) ali z zdravilom izzvano levkopenijo/nevtropenijo je treba skrbno spremljati prve mesece zdravljenja.
• low blood pressure upon standing (consequently, some people taking INVEGA may feel faint, 
• nizek krvni tlak ob vstajanju (nekateri bolniki, ki jemljejo zdravilo INVEGA, so posledično lahko posledično omotični, omedlijo ali izgubijo zavest, ko vstanejo ali se nanadoma vsedejo),
The recommended starting dose for treating schizophrenia in adolescents 15 years and older is 3 mg once a day taken in the morning. 
Priporočeni začetni odmerek za zdravljenje shizofrenije pri mladostnikih, starih 15 let in več je 3 mg enkrat na dan zjutraj.
However, there was no discernable effect of age in the population pharmacokinetic analysis involving schizophrenia subjects after correction of age-related decreases in CrCl. 
V analizi populacijske farmakokinetike pri preiskovancih s shizofrenijo pa ni bilo vidnega vpliva starosti po korekciji za starostno zmanjšanje očistka kreatinina.
Metabolism and nutrition disorders weight increased, increased appetite, weight decreased, decreased appetite diabetes mellitus d, 
Presnovne in prehranske motnje zvečana telesna masa, povečan tek, zmanjšana telesna masa, zmanjšan apetit sladkorna bolezen d,
Paliperidone should be used with caution in patients with possible prolactin-dependent tumours. 
Pri bolnikih z morebitnimi, od prolaktina odvisnimi tumorji je treba paliperidon uporabljati previdno.
Adolescents weighing < 51 kg: the maximum recommended daily dose of INVEGA is 6 mg. 
Mladostniki s telesno maso < 51 kg: največji priporočeni dnevni odmerek zdravila INVEGA je 6 mg.
After having been successfully treated for an acute psychotic or mood episode for 13 weeks and stabilised for an additional 12 weeks with the long-acting injectable formulation of paliperidone (doses ranging from 50 to 150 mg) patients were then randomised to a 15-month double-blind relapse prevention period of the study to either continue on the long-acting injectable formulation of paliperidone or on placebo until they experienced a relapse of schizoaffective symptoms. 
Po uspešnem 13-tedenskem zdravljenju akutne psihotične epizode in nihanja razpoloženja ter stabilizacij stanja z injekcijami paliperidona s podaljšanim sproščanjem dodatnih 12 tednov (odmerki so bili v razponu od 50 do 150 mg), so bolnike randomizirali v 15-mesečno dvojno slepo obdobje preprečevanja relapsov v dve skupini.
Blood and lymphatic system disorders white blood cell count decreased, thrombocytopenia, anaemia, haematocrit decreased agranulocytosis c, 
Bolezni krvi in limfatičnega sistema levkopenija, trombocitopenija, anemija, zmanjšan hematokrit agranulocitoza c,
Vascular disorders orthostatic hypotension, hypertension hypotension pulmonary embolism, venous thrombosis, 
Žilne bolezni ortostatska hipotenzija, hipertenzija hipotenzija pljučna embolija, venska tromboza, ishemija, rdečica
Not observed in INVEGA clinical studies but observed in post-marketing environment with paliperidone In placebo-controlled pivotal trials, diabetes mellitus was reported in 0.05% in INVEGA-treated subjects compared to a rate of 0% in placebo group. 
V s placebom nadzorovanih ključnih preskušanjih so pri bolnikih, zdravljenih z zdravilom INVEGA, poročali o sladkorni bolezni pri 0,05% bolnikov v primerjavi z 0% bolnikov v skupini, ki je prejemala placebo.
After having been treated for an acute episode for 6 weeks and stabilised for an additional 8 weeks with INVEGA (doses ranging from 3 to 15 mg once daily) patients were then randomised in a double-blind manner to either continue on INVEGA or on placebo until they experienced a relapse in schizophrenia symptoms. 
Po 6-tedenskem zdravljenju akutne epizode z zdravilom INVEGA (odmerki so bili v razponu od 3 do 15 mg enkrat na dan) in stabilizaciji stanja v dodatnih 8 tednih so bolnike randomizirali na dvojno slep način v dve skupini: ena je nadaljevala zdravljenje z zdravilom INVEGA, druga pa je jemala placebo, dokler se niso ponovili simptomi shizofrenije.
Paliperidone is not expected to cause clinically important pharmacokinetic interactions with medicines that are metabolised by cytochrome P-450 isozymes. 
Možnost, da bo zdravilo INVEGA vplivalo na druga zdravila Ni pričakovati, da bi paliperidon povzročil klinično pomembne farmakokinetične interakcije z zdravili, ki se presnavljajo z izoencimi citokroma P-450.
Infections and infestations bronchitis, upper respiratory tract infection, sinusitis, urinary tract infection, influenza pneumonia, respiratory tract infection, cystitis, ear infection, tonsillitis eye infection, onychomycosis, cellulitis, acarodermatitis 
Infekcijske in parazitske bolezni bronhitis, okužba zgornjih dihal, sinuzitis, okužba sečil, gripa pljučnica, okužba dihal, cistitis, okužba ušesa, tonzilitis okužba očesa, onihomikoza, celulitis, akarodermatitis
• chest pain, chest discomfort, feeling unwell 
• bolečina v prsih, nelagodje v prsih, slabo počutje
Antipsychotic medicinal products (including risperidone) with α-adrenergic blocking effects have been reported to induce priapism. 
Poročali so, da antipsihotiki z zaviralnim delovanjem na adrenergične receptorje alfa (vključno z risperidonom) povzročajo priapizem.
INVEGA is indicated for the treatment of schizophrenia in adults and in adolescents 15 years and older. 
Zdravilo INVEGA je indicirano za zdravljenje shizofrenije pri odraslih in mladostnikih, starih 15 let in več.
Abnormalities of electrical function in the heart may occur when this medicine is taken with certain heart medicines that control heart rhythm, or some other types of medicines such as antihistamines, antimalarials, or other antipsychotics. 
Če to zdravilo jemljete z določenimi zdravili za srce, ki nadzorujejo srčni ritem ali z nekaterimi zdravili kot so antihistaminiki, antimalariki ali z drugimi antipsihotiki, se lahko pojavijo nepravilnosti v električni funkciji srca.
• thickening of the skin, dry skin, skin redness, skin discolouration, flaky itchy scalp or skin, 
• stanjšanje kože, suha koža, rdečica kože, razbarvanje kože, luskasta, srbeča koža skalpa, prhljaj
For adolescents weighing less than 51 kg the dose may be increased to 6 mg once a day. 
Pri mladostnikih s telesno maso manjšo od 51 kg in več se odmerek zdravila lahko poveča na 6 mg enkrat na dan.
What INVEGA looks like and contents of the pack INVEGA prolonged-release tablets are capsule shaped. 
INVEGA tablete s podaljšanim sproščanjem so v obliki kapsule.
Take this medicine exactly as the doctor, pharmacist or nurse has told you to. 
Pri jemanju tega zdravila natančno upoštevajte navodila zdravnika, farmacevta ali medicinske sestre.
CARTON FOR PVC-PCTFE/ALUMINIUM BLISTER (for white and clear blister) 
ŠKATLA ZA PRETISNE OMOTE IZ PVC-PCTFE/ALU (za bele in prozorne pretisne omote)
• breast swelling in boys 
• otekanje prsi pri fantih
7 TABLET OPA-ALU-PVC/ALU BLISTER 
PRETISNI OMOTI IZ OPA-ALU-PVC/ALU S 7 TABLETAMI
The safety and efficacy of INVEGA in the treatment of schizophrenia in adolescents between 12 and 14 years old has not been established. 
Varnost in učinkovitost zdravila INVEGA pri zdravljenju shizofrenije pri mladostnikih, starih med 12 in 14 let nista bili dokazani.
When dose increases are indicated, increments of 3 mg/day are recommended and generally should occur at intervals of 5 days or more. 
Kadar je indicirano povečanje odmerka, je priporočeno povečevanje po 3 mg na dan, v intervalih po 5 dni ali več.
In vitro studies indicate that CYP2D6 and CYP3A4 may be minimally involved in paliperidone metabolism, but there are no indications in vitro nor in vivo that these isozymes play a significant role in the metabolism of paliperidone. 
Možnost, da bodo druga zdravila vplivala na zdravilo INVEGA In vitro študije kažejo, da izoencima CYP2D6 in CYP3A4 lahko minimalno sodelujeta v presnovi paliperidona, vendar ni nikakršnih znakov in vitro ali in vivo, da bi imela ta dva izoencima pomembno vlogo pri presnovi paliperidona.
• pneumonia, infection of the breathing passages, bladder infection, ear infection, tonsillitis 
• pljučnica, okužba dihalnih poti, okužba sečnega mehurja, okužba v ušesu, tonzilitis (vnetje mandljev)
Polyethylene glycol 400 (6, 9 and 12 mg tablet only) Ferric Oxide (Yellow) (E172) (6, 12 mg tablet only) Ferric Oxide (Red) (E172) ( 6, 9 mg tablet only) Lactose monohydrate (3 mg tablet only) Triacetin (3 mg tablet only) Carnauba wax 
Obloga: hipromeloza titanov dioksid (E171) makrogol 400 (samo v 6 mg, 9 mg in 12 mg tabletah) rumeni železov oksid (E172) (samo v 6 mg in 12 mg tabletah) rdeči železov oksid (E172) (samo v 6 mg in 9 mg tabletah) laktoza monohidrat (samo v 3 mg tabletah) triacetin (samo v 3 mg tabletah) karnauba vosek
- if you have liver problems. 
- Če imate težave z delovanjem ledvic.
pollakiuria, urinary retention, dysuria 
Bolezni sečil inkontinenca urina, polakiurija, retenca urina, disurija
Nervous system disorders parkinsonism , akathisia b, 
Bolezni živčevja parkinsonizem b,
Blisters: Do not store above 30°C. 
Shranjujte pri temperaturi do 30 C.
Torsade de pointes and ventricular fibrillation have been reported in association with overdose. 
Pri prevelikem odmerjanju so poročali o torsade de pointes in fibrilaciji ventriklov.
• sore throat, cough, stuffy nose 
• vneto grlo, kašelj, zamašen nos
For adolescents weighing 51 kg or more the dose may be increased within the range of 6 mg to 12 mg once a day. 
Pri mladostnikih s telesno maso 51 kg in več se odmerek zdravila lahko poveča od 6 mg do 12 mg enkrat na dan.
In schizophrenia clinical trials, the proportions of subjects meeting a weight gain criterion of ≥ 7% of body weight were compared, revealing a similar incidence of weight gain for INVEGA 3 mg and 6 mg compared with placebo, and a higher incidence of weight gain for INVEGA 9 mg and 12 mg compared with placebo. 
Primerjava je pokazala podobno incidenco povečanja telesne mase pri zdravilu INVEGA 3 mg in 6 mg kot pri placebu in večjo incidenco povečanja telesne mase pri zdravilu INVEGA 9 mg in 12 mg v primerjavi s placebom.
Although in vitro studies suggested a role for CYP2D6 and CYP3A4 in the metabolism of paliperidone, there is no evidence in vivo that these isozymes play a significant role in the metabolism of paliperidone. 
Čeprav študije in vitro kažejo, da pri presnovi paliperidona sodelujeta tudi CYP2D6 in CYP3A4, ni nikakršnih dokazov in vivo, da bi bila ta dva izoencima pomembna pri presnovi paliperidona.
The active substance is paliperidone 
Učinkovina je paliperidon.
INVEGA is used to treat schizophrenia in adults and in adolescents aged 15 years and older. 
Zdravilo INVEGA se uporablja za zdravljenje shizofrenije pri odraslih in mladostnikih, starih 15 let in več.
Dosage adjustment, if indicated, should occur only after clinical reassessment. 
Če je potrebno prilagajanje odmerka, ga lahko opravite šele po ponovni klinični oceni bolnikovega stanja.
In the schizoaffective disorder studies, a greater proportion of subjects in the total INVEGA dose group who were receiving concomitant therapy with an antidepressant or mood stabiliser experienced adverse events as compared to those subjects treated with INVEGA monotherapy. 
V študijah shizoafektivne motnje so se v skupini, ki je prejemala zdravilo INVEGA, neželeni učinki pojavili pri večjem deležu preiskovancev, ki so prejemali sočasno zdravljenje z antidepresivi ali stabilizatorji razpoloženja, kot pri preiskovancih, ki so prejemali samostojno zdravljenje z zdravilom INVEGA.
Elderly Your doctor may reduce your dose of medicine if your kidney function is reduced. 
Starostniki Če je delovanje vaših ledvic oslabljeno, vam bo morda zdravnik zmanjšal odmerek zdravila.
waist circumference increased, anorexia, blood triglycerides increased water intoxication, diabetic ketoacidosis c, hypoglycaemia, polydipsia, blood cholesterol increased hyperinsulinaemi 
hiperglikemija, povečan obseg pasu, anoreksija, zvišana koncentracija trigliceridov v krvi zastrupitev z vodo, diabetična ketoacidoza c, hipoglikemija, polidipsija, zvišana koncentracija holesterola v krvi hiperinsulinemija
• blood vessel problems in the brain, coma due to uncontrolled diabetes, unresponsive to stimuli, 
• težave s krvnimi žilami v možganih, koma zaradi neurejene sladkorne bolezni, neodzivnost na dražljaje, zmanjšana stopnja zavesti, tresenje glave
Your doctor will decide how much to give you. 
Odmerek vam bo določil vaš zdravnik.
Menstrual disorder includes: menstruation irregular, oligomenorrhoea 
Motnje menstruacije vključujejo: neredne menstruacije, oligomenorejo.
In the pooled adolescent schizophrenia population (12 years and older, N = 545) exposed to INVEGA, the frequency and type of undesirable effects were similar to those in adults except for the following ADRs that were reported more frequently in adolescents receiving INVEGA than adults receiving INVEGA (and more frequently than placebo): sedation/somnolence, parkinsonism, weight increase, upper respiratory tract infection, akathisia, and tremor were reported very commonly (≥ 1/10) in adolescents; abdominal pain, galactorrhoea, gynaecomastia, acne, dysarthria, gastroenteritis, epistaxis, ear infection, blood triglyceride increased, and vertigo were reported commonly (≥ 1/100, < 1/10) in adolescents. 
O naslednjih neželenih učinkih pa so pri mladostnikih, ki so prejemali zdravilo INVEGA poročali pogosteje kot pri odraslih, ki so prejemali zdravilo INVEGA (in pogosteje kot pri placebu): pri mladostnikih so o sedaciji/somnolenci, parkinsonizmu, povečanju telesne mase, okužbi zgornjih dihal, akatiziji in tremorju poročali zelo pogosto (≥ 1/10); o bolečini v trebuhu, galaktoreji, ginekomastiji, aknah, dizartriji, gastroenteritisu, epistaksi, okužbi ušesa, povečani koncentraciji trigliceridov v krvi in vrtoglavici pa pogosto (≥ 1/100, < 1/10).
The ADRs that appeared to be dose-related included headache, sedation/somnolence, parkinsonism, akathisia, tachycardia, dystonia, dizziness, tremor, upper respiratory tract infection, dyspepsia, and musculoskeletal pain. 
Neželeni učinki, ki so bili odvisni od odmerka, so bili glavobol, sedacija/somnolenca, parkinsonizem, akatizija, tahikardija, distonija, omotica, tremor, okužba zgornjih dihal, dispepsija in mišično-skeletna bolečina.
Dosage reduction for INVEGA should be considered when INVEGA is co-administered with valproate after clinical assessment. 
Kadar se zdravilo INVEGA uporablja sočasno z valproatom, je treba po klinični oceni pretehtati možnost zmanjšanja odmerka zdravila INVEGA.
• a delay in menstrual periods, breast enlargement 
• zapoznela menstruacija, povečanje prsi
Respiratory, thoracic and mediastinal disorders pharyngolarynge al pain, cough, nasal congestion dyspnoea, wheezing, epistaxis sleep apnoea syndrome, hyperventilation, pneumonia aspiration, respiratory tract congestion, dysphonia pulmonary congestion 
Bolezni dihal, prsnega koša in mediastinalnega prostora faringolaringealna bolečina, kašelj, kongestija nosne sluznice dispneja, sopihanje, epistaksa sindrom apneje v spanju, hiperventilacija, aspiracijska pljučnica, kongestija dihal, disfonija pljučna kongestija
White polyvinyl chloride (PVC) laminated with polychloro-trifluoroethylene (PCTFE)/aluminium push-through layer. 
ali bel polivinilklorid (PVC) laminiran s polikloro-trifluoroetilenom (PCTFE)/aluminijevo pretisno plastjo.